Cargando…
Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database
The treatment of multiple myeloma has dramatically improved due to the availability of novel therapies that are highly effective and are quickly moving into first-line therapy. The Canadian Agency for Drugs and Technologies in Health (CADTH) recently recommended that patients who receive daratumumab...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946875/ https://www.ncbi.nlm.nih.gov/pubmed/35323332 http://dx.doi.org/10.3390/curroncol29030132 |
_version_ | 1784674295918624768 |
---|---|
author | McCurdy, Arleigh Venner, Christopher P. Masih-Khan, Esther Louzada, Martha LeBlanc, Richard Sebag, Michael Song, Kevin Jimenez-Zepeda, Victor H. Kotb, Rami Kardjadj, Moustafa Mian, Hira White, Darrell Stakiw, Julie Aslam, Muhammad Reiman, Anthony Gul, Engin Reece, Donna |
author_facet | McCurdy, Arleigh Venner, Christopher P. Masih-Khan, Esther Louzada, Martha LeBlanc, Richard Sebag, Michael Song, Kevin Jimenez-Zepeda, Victor H. Kotb, Rami Kardjadj, Moustafa Mian, Hira White, Darrell Stakiw, Julie Aslam, Muhammad Reiman, Anthony Gul, Engin Reece, Donna |
author_sort | McCurdy, Arleigh |
collection | PubMed |
description | The treatment of multiple myeloma has dramatically improved due to the availability of novel therapies that are highly effective and are quickly moving into first-line therapy. The Canadian Agency for Drugs and Technologies in Health (CADTH) recently recommended that patients who receive daratumumab should only be eligible to receive either carfilzomib or pomalidomide but not both, for relapsed MM. In order to assess the efficacy of these two agents in the relapsed setting, we utilized our national myeloma database. A total of 121 patients were reviewed, 49 patients received CAR- before POM-based (CAR-POM), and 73 patients received POM- before CAR-based (POM-CAR) therapy. In the groups selected, the median PFS was 4.93 months (95% CI, 2.76–7.07) and 5.36 months (95% CI, 3.75–6.94) for CAR-POM and POM-CAR, respectively. The median OS for patients treated with CAR-POM was 11.01 months (95% CI, 4.50–19.13), and for patients treated with POM-CAR the median OS was 10.98 months (95% CI, 8.98–19.17). In this real-world observational study, we demonstrated that both CAR- and POM-based therapies, irrespective of the order in which they were used, were effective treatment options for patients with advanced relapsed MM. |
format | Online Article Text |
id | pubmed-8946875 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-89468752022-03-25 Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database McCurdy, Arleigh Venner, Christopher P. Masih-Khan, Esther Louzada, Martha LeBlanc, Richard Sebag, Michael Song, Kevin Jimenez-Zepeda, Victor H. Kotb, Rami Kardjadj, Moustafa Mian, Hira White, Darrell Stakiw, Julie Aslam, Muhammad Reiman, Anthony Gul, Engin Reece, Donna Curr Oncol Brief Report The treatment of multiple myeloma has dramatically improved due to the availability of novel therapies that are highly effective and are quickly moving into first-line therapy. The Canadian Agency for Drugs and Technologies in Health (CADTH) recently recommended that patients who receive daratumumab should only be eligible to receive either carfilzomib or pomalidomide but not both, for relapsed MM. In order to assess the efficacy of these two agents in the relapsed setting, we utilized our national myeloma database. A total of 121 patients were reviewed, 49 patients received CAR- before POM-based (CAR-POM), and 73 patients received POM- before CAR-based (POM-CAR) therapy. In the groups selected, the median PFS was 4.93 months (95% CI, 2.76–7.07) and 5.36 months (95% CI, 3.75–6.94) for CAR-POM and POM-CAR, respectively. The median OS for patients treated with CAR-POM was 11.01 months (95% CI, 4.50–19.13), and for patients treated with POM-CAR the median OS was 10.98 months (95% CI, 8.98–19.17). In this real-world observational study, we demonstrated that both CAR- and POM-based therapies, irrespective of the order in which they were used, were effective treatment options for patients with advanced relapsed MM. MDPI 2022-03-02 /pmc/articles/PMC8946875/ /pubmed/35323332 http://dx.doi.org/10.3390/curroncol29030132 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Brief Report McCurdy, Arleigh Venner, Christopher P. Masih-Khan, Esther Louzada, Martha LeBlanc, Richard Sebag, Michael Song, Kevin Jimenez-Zepeda, Victor H. Kotb, Rami Kardjadj, Moustafa Mian, Hira White, Darrell Stakiw, Julie Aslam, Muhammad Reiman, Anthony Gul, Engin Reece, Donna Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database |
title | Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database |
title_full | Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database |
title_fullStr | Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database |
title_full_unstemmed | Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database |
title_short | Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database |
title_sort | sequential use of carfilzomib and pomalidomide in relapsed multiple myeloma: a report from the canadian myeloma research group (cmrg) database |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946875/ https://www.ncbi.nlm.nih.gov/pubmed/35323332 http://dx.doi.org/10.3390/curroncol29030132 |
work_keys_str_mv | AT mccurdyarleigh sequentialuseofcarfilzomibandpomalidomideinrelapsedmultiplemyelomaareportfromthecanadianmyelomaresearchgroupcmrgdatabase AT vennerchristopherp sequentialuseofcarfilzomibandpomalidomideinrelapsedmultiplemyelomaareportfromthecanadianmyelomaresearchgroupcmrgdatabase AT masihkhanesther sequentialuseofcarfilzomibandpomalidomideinrelapsedmultiplemyelomaareportfromthecanadianmyelomaresearchgroupcmrgdatabase AT louzadamartha sequentialuseofcarfilzomibandpomalidomideinrelapsedmultiplemyelomaareportfromthecanadianmyelomaresearchgroupcmrgdatabase AT leblancrichard sequentialuseofcarfilzomibandpomalidomideinrelapsedmultiplemyelomaareportfromthecanadianmyelomaresearchgroupcmrgdatabase AT sebagmichael sequentialuseofcarfilzomibandpomalidomideinrelapsedmultiplemyelomaareportfromthecanadianmyelomaresearchgroupcmrgdatabase AT songkevin sequentialuseofcarfilzomibandpomalidomideinrelapsedmultiplemyelomaareportfromthecanadianmyelomaresearchgroupcmrgdatabase AT jimenezzepedavictorh sequentialuseofcarfilzomibandpomalidomideinrelapsedmultiplemyelomaareportfromthecanadianmyelomaresearchgroupcmrgdatabase AT kotbrami sequentialuseofcarfilzomibandpomalidomideinrelapsedmultiplemyelomaareportfromthecanadianmyelomaresearchgroupcmrgdatabase AT kardjadjmoustafa sequentialuseofcarfilzomibandpomalidomideinrelapsedmultiplemyelomaareportfromthecanadianmyelomaresearchgroupcmrgdatabase AT mianhira sequentialuseofcarfilzomibandpomalidomideinrelapsedmultiplemyelomaareportfromthecanadianmyelomaresearchgroupcmrgdatabase AT whitedarrell sequentialuseofcarfilzomibandpomalidomideinrelapsedmultiplemyelomaareportfromthecanadianmyelomaresearchgroupcmrgdatabase AT stakiwjulie sequentialuseofcarfilzomibandpomalidomideinrelapsedmultiplemyelomaareportfromthecanadianmyelomaresearchgroupcmrgdatabase AT aslammuhammad sequentialuseofcarfilzomibandpomalidomideinrelapsedmultiplemyelomaareportfromthecanadianmyelomaresearchgroupcmrgdatabase AT reimananthony sequentialuseofcarfilzomibandpomalidomideinrelapsedmultiplemyelomaareportfromthecanadianmyelomaresearchgroupcmrgdatabase AT gulengin sequentialuseofcarfilzomibandpomalidomideinrelapsedmultiplemyelomaareportfromthecanadianmyelomaresearchgroupcmrgdatabase AT reecedonna sequentialuseofcarfilzomibandpomalidomideinrelapsedmultiplemyelomaareportfromthecanadianmyelomaresearchgroupcmrgdatabase |